门性高血压的药物治疗方法:当前状态和扩大指示
Mohamed A Elfeki1, Ashwani K Singal1,2,3, Patrick S Kamath4
1Avera McKennan University Hospital, Sioux Falls, SD.
非选择性β抑制剂是预防水出血的关键. 卡维迪洛尔在预防肝脏衰减和改善 portal高血压患者的存活率方面表现有前途,使用非侵入性方法帮助诊断.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 药理学 药理学是指药理学的学科.
- 胃肠病学 胃肠病学
背景情况:
- 非选择性β抑制剂是预防水出血及其复发的标准药物治疗.
- 门高血压管理对于预防严重并发症至关重要.
研究的目的:
- 审查目前和新兴的门性高血压的药理疗法.
- 更新有关使用β-阻断剂来管理门脉高血压的知识.
主要方法:
- 对门高血压的药理疗法的文献综述.
- 对卡维迪醇和非侵入性诊断标记物的最新数据的分析.
主要成果:
- 与nadolol和propranolol相比,carvedilol在降低门口压力方面表现出更高的有效性.
- 非侵入性测试,包括肝硬度测量和血小板计数,可以准确地确定临床上显著的门性高血压.
- 卡维迪醇的使用正在扩大,以减少临床显著的门性高血压患者的肝衰竭风险.
结论:
- 卡维迪洛尔是门高血压管理的高效药物.
- 非侵入性方法对于识别可能受益于卡维迪醇治疗的患者是有价值的.
- 需要对非侵入性生物标志物的进一步研究,以优化药理治疗策略.
更多相关视频
09:37Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats
Published on: August 1, 2018
04:00Laparoscopic Splenectomy with Pericardial Devascularization for Hypersplenism and Esophageal Variceal Hemorrhage Due to Portal Hypertension
Published on: November 15, 2024
相关概念视频
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
Esophageal Varices-I: Introduction
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
